Vanda Pharmaceuticals (VNDA) Competitors $4.60 -0.07 (-1.39%) Closing price 03:58 PM EasternExtended Trading$4.60 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VNDA vs. GERN, RGLS, ZBIO, MYGN, RIGL, EBS, VSTM, XOMA, LXRX, and CDXSShould you be buying Vanda Pharmaceuticals stock or one of its competitors? The main competitors of Vanda Pharmaceuticals include Geron (GERN), Regulus Therapeutics (RGLS), Zenas Biopharma (ZBIO), Myriad Genetics (MYGN), Rigel Pharmaceuticals (RIGL), Emergent BioSolutions (EBS), Verastem (VSTM), XOMA (XOMA), Lexicon Pharmaceuticals (LXRX), and Codexis (CDXS). These companies are all part of the "biotechnology" industry. Vanda Pharmaceuticals vs. Geron Regulus Therapeutics Zenas Biopharma Myriad Genetics Rigel Pharmaceuticals Emergent BioSolutions Verastem XOMA Lexicon Pharmaceuticals Codexis Vanda Pharmaceuticals (NASDAQ:VNDA) and Geron (NASDAQ:GERN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings, media sentiment and community ranking. Which has more risk & volatility, VNDA or GERN? Vanda Pharmaceuticals has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500. Comparatively, Geron has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500. Do analysts prefer VNDA or GERN? Vanda Pharmaceuticals presently has a consensus target price of $16.50, indicating a potential upside of 251.06%. Geron has a consensus target price of $5.06, indicating a potential upside of 221.43%. Given Vanda Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Vanda Pharmaceuticals is more favorable than Geron.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vanda Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Geron 0 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.78 Does the media refer more to VNDA or GERN? In the previous week, Vanda Pharmaceuticals had 4 more articles in the media than Geron. MarketBeat recorded 7 mentions for Vanda Pharmaceuticals and 3 mentions for Geron. Geron's average media sentiment score of 1.18 beat Vanda Pharmaceuticals' score of 1.03 indicating that Geron is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vanda Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Geron 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation & earnings, VNDA or GERN? Vanda Pharmaceuticals has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVanda Pharmaceuticals$201.35M1.38-$18.90M-$0.75-6.27Geron$116.29M8.63-$184.13M-$0.21-7.50 Do insiders & institutionals have more ownership in VNDA or GERN? 88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. Comparatively, 73.7% of Geron shares are owned by institutional investors. 10.0% of Vanda Pharmaceuticals shares are owned by insiders. Comparatively, 7.4% of Geron shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is VNDA or GERN more profitable? Vanda Pharmaceuticals has a net margin of -9.51% compared to Geron's net margin of -682.48%. Vanda Pharmaceuticals' return on equity of -3.49% beat Geron's return on equity.Company Net Margins Return on Equity Return on Assets Vanda Pharmaceuticals-9.51% -3.49% -2.90% Geron -682.48%-67.53%-45.46% Does the MarketBeat Community believe in VNDA or GERN? Vanda Pharmaceuticals received 46 more outperform votes than Geron when rated by MarketBeat users. However, 69.93% of users gave Geron an outperform vote while only 66.42% of users gave Vanda Pharmaceuticals an outperform vote. CompanyUnderperformOutperformVanda PharmaceuticalsOutperform Votes54666.42% Underperform Votes27633.58% GeronOutperform Votes50069.93% Underperform Votes21530.07% SummaryVanda Pharmaceuticals beats Geron on 11 of the 18 factors compared between the two stocks. Get Vanda Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VNDA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VNDA vs. The Competition Export to ExcelMetricVanda PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$276.99M$6.85B$5.58B$8.67BDividend YieldN/A2.49%5.27%4.19%P/E Ratio-14.698.8227.2320.12Price / Sales1.38263.82423.64161.29Price / CashN/A65.8538.2534.64Price / Book0.516.657.114.72Net Income-$18.90M$143.49M$3.23B$247.80M7 Day Performance5.86%4.70%3.67%2.77%1 Month Performance18.69%15.02%13.11%9.75%1 Year Performance-21.54%5.96%32.12%15.01% Vanda Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VNDAVanda Pharmaceuticals4.569 of 5 stars$4.60-1.4%$16.50+259.1%-22.1%$270.80M$201.35M-14.36290News CoveragePositive NewsAnalyst RevisionGERNGeron3.0977 of 5 stars$1.43-5.9%$5.06+254.0%-68.3%$910.79M$116.29M-4.4770Positive NewsRGLSRegulus Therapeutics2.2178 of 5 stars$7.94+0.1%$8.50+7.1%+238.8%$549.72MN/A-7.4230Positive NewsZBIOZenas Biopharma1.2374 of 5 stars$10.06+5.7%$36.67+264.5%N/A$420.85M$15M-2.83N/ATrending NewsHigh Trading VolumeMYGNMyriad Genetics4.0941 of 5 stars$4.46+6.4%$14.79+231.5%-76.4%$411.11M$831.30M-3.432,600High Trading VolumeRIGLRigel Pharmaceuticals2.9661 of 5 stars$20.15+4.9%$36.40+80.6%+111.4%$360.12M$203.08M143.94160Positive NewsAnalyst RevisionEBSEmergent BioSolutions4.231 of 5 stars$6.30-0.3%$14.33+127.5%+5.5%$341.95M$930.30M-1.542,420VSTMVerastem2.6817 of 5 stars$6.02-19.9%$13.63+126.3%+84.3%$330.79M$10M-1.8950Positive NewsHigh Trading VolumeXOMAXOMA4.5141 of 5 stars$24.22-2.2%$69.50+187.0%+7.3%$289.84M$13.05M-6.9610Positive NewsLXRXLexicon Pharmaceuticals2.6186 of 5 stars$0.62-0.8%$3.67+489.9%-63.1%$224.70M$31.21M-0.83140Positive NewsCDXSCodexis3.6057 of 5 stars$2.25-2.2%$8.00+255.6%-25.6%$186.40M$49.82M-2.59250Positive NewsAnalyst Revision Related Companies and Tools Related Companies Geron Competitors Regulus Therapeutics Competitors Zenas Biopharma Competitors Myriad Genetics Competitors Rigel Pharmaceuticals Competitors Emergent BioSolutions Competitors Verastem Competitors XOMA Competitors Lexicon Pharmaceuticals Competitors Codexis Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VNDA) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vanda Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vanda Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VNDA Stock Free VNDA Stock Alerts